STOCK TITAN
  1. Home
  2. News
  3. JAGX

Jaguar Health Inc - JAGX STOCK NEWS

Welcome to our dedicated news page for Jaguar Health (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jaguar Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jaguar Health's position in the market.

News
Jaguar Health Enters Exclusive Crofelemer Revenue Sharing License and Commercialization Agreement with Quadri Pharmaceuticals Store for Rare Intestinal Failure Diseases in Middle East Markets
Rhea-AI Summary
Napo Pharmaceuticals, a Jaguar Health family company, has entered a revenue sharing license and commercialization agreement with Quadri Pharmaceuticals Store. The agreement grants Quadri Pharma exclusive rights to promote, commercialize, and distribute a powder formulation of crofelemer for rare disease indications in multiple Middle East countries. Quadri Pharma will cover 50% of the development costs for three years. Napo will host a virtual educational webinar on intestinal failure with leading experts on November 8th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.05%
Tags
none
-
News
Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
Rhea-AI Summary
Napo Pharmaceuticals, a Jaguar Health company, has been issued a new U.S. patent for methods of treating rare diseases using crofelemer. The patent enhances the intellectual property protection for crofelemer for the treatment of short bowel syndrome (SBS). Jaguar is supporting studies of crofelemer for SBS and microvillus inclusion disease (MVID) in multiple regions, with results expected by the end of 2023 and 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
none
-
News
Magdalena Biosciences, a Joint Venture between Jaguar Health and Filament Health, Receives Second Tranche of Funding from One Small Planet
Rhea-AI Summary
Magdalena Biosciences, a joint venture between Jaguar Health and Filament Health Corp., has received the second tranche of funding from One Small Planet. The collaboration aims to develop natural prescription medicines derived from plants for mental health indications. The funding commitment is for US$1,000,000, payable in quarterly installments based on defined milestones. The joint venture will leverage Jaguar's library of 2,300 medicinal plants and 3,500 plant extracts to develop pharmaceutical-grade drugs for conditions such as ADHD, depression, and anxiety. The global ADHD market is projected to reach US$18.69 billion by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.62%
Tags
none
News
Jaguar Health to Present November 1st at Emerging Growth Conference
Rhea-AI Summary
Jaguar Health CEO to present at Emerging Growth Conference on November 1, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
conferences acquisition
-
News
Independent Study Conducted at Boston Children's Hospital, Harvard Medical School, Shows Potential Utility of Jaguar Health's Crofelemer for Treatment of MVID, a Rare Childhood Disease
Rhea-AI Summary
Jaguar Health announces publication of study evaluating crofelemer for the treatment of microvillus inclusion disease (MVID)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.92%
Tags
none
-
News
Napo Pharmaceuticals to Exhibit at the October 25-28 Annual Association of Nurses in AIDS Care (ANAC) Conference for Mytesi, the Company’s FDA-Approved Prescription Drug
Rhea-AI Summary
Napo Pharmaceuticals to exhibit at Annual Association of Nurses in AIDS Care Conference and host educational dinner for nurses about HIV-related diarrhea and Mytesi
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
none
News
Jaguar Health to Present October 17 at the Lytham Partners Fall 2023 Investor Conference and October 18 at the BIO Investor Forum
Rhea-AI Summary
Jaguar Health announces upcoming results for phase 3 OnTarget trial of crofelemer for cancer therapy-related diarrhea. Lisa Conte to present at investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
46.28%
Tags
conferences
-
News
Jaguar Animal Health Exhibiting at October 12-14 VCS Annual Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
Rhea-AI Summary
Jaguar Health announces exhibition at Veterinary Cancer Society Annual Conference for Canalevia-CA1
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
none
-
News
Jaguar Health to Present October 3 at LD Micro's Main Event Investor Conference, and on October 5 at the Global Capital Network Investor Conference
Rhea-AI Summary
Jaguar Health expects top-line results for their phase 3 OnTarget trial of crofelemer for cancer therapy-related diarrhea by late October 2023. They are also supporting proof-of-concept studies for crofelemer in rare disease indications with results expected in 2023 and 2024. Jaguar management will be presenting at investor conferences in October. Napo Pharmaceuticals, a Jaguar family company, has completed the stage 1 primary endpoint treatment period for their Phase 3 OnTarget trial of crofelemer for cancer patients with diarrhea. Top-line results for this trial are expected in late October 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
conferences
News
Jaguar Health Launches TikTok and Instagram Contest to Raise Awareness About Common Yet Barely Addressed Health Condition: Surprise Diarrhea
Rhea-AI Summary
Napo Pharmaceuticals launches Surprise Diarrhea Lip-Syncing and Singing contest to raise awareness about chronic diarrhea in people living with HIV. Winners receive prize money, bidets, and donations to qualified nonprofits. Contest runs from September 27 to November 1. Significant advances have been made in HIV treatment, but 87% of long-term survivors still experience chronic diarrhea. Contest aims to end stigma and shame around the condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
none
Stock JAGX logo
Jaguar Health Inc

Nasdaq:JAGX

JAGX Rankings

#4732 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

JAGX Stock Data

24.94M
274.29M
1.78%
0.45%
8.5%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Francisco

About JAGX

jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/